08:02 AM EST, 01/14/2025 (MT Newswires) -- TG Therapeutics ( TGTX ) said Tuesday that it expects Q4 Briumvi US net product revenue of $103.6 million.

The company said its cash position at the end of 2024 was $310 million.

TG Therapeutics ( TGTX ) said it expects 2025 total global revenue of $540 million, including Briumvi US net product revenue of $525 million. Analysts polled by Capital IQ are looking for total revenue of $537.8 million.

Shares of the company were up more than 5% in recent premarket activity.

Price: 29.16, Change: +1.49, Percent Change: +5.38